Physician profile
Min Yang
NPI 1255574000
$6,756.27
in general payments reported to CMS, 2019-2025
23 companies · $1,712 in 2025
The $1,712 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $666 · 2022: $1,185 · 2023: $1,529 · 2024: $1,664 · 2025: $1,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,905.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,125.34 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $991.40 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $729.87 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $607.72 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $571.48 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Beigene USA, INC. | $400.00 | 2021-2023 | Brukinsa |
| Exact Sciences Corporation | $363.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $312.05 | 2021-2024 | Eliquis, Camzyos |
| Pfizer INC. | $254.98 | 2021-2025 | |
| Glaxosmithkline, LLC. | $246.39 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $211.15 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $168.26 | 2021-2025 | |
| Amarin Pharma, INC. | $143.16 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $125.00 | 2021 | |
| Abbvie INC. | $104.93 | 2022-2025 | Synthroid, Ubrelvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $98.00 | 2023-2024 | Xarelto |
| Abbott Laboratories | $90.35 | 2023-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $70.07 | 2022 | |
| Paratek Pharmaceuticals, INC. | $67.75 | 2022-2024 | Nuzyra |
| Nestle Healthcare Nutrition INC. | $23.66 | 2022 | |
| Recor Medical INC | $20.70 | 2025 | Paradise Ultrasound Renal Denervation System |
| Medtronic, INC. | $17.63 | 2025 | Venaseal |
| Esperion Therapeutics, INC. | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.